|
1)Neurotoxicity
of FOLFOX-4 as adjuvant treatment for patients with colon and
gastric cancer: a randomized study of two different schedules of
oxaliplatin.
Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi
R, Civitelli S, Tanzini G, Lorenzi M, Francini G.
Cancer Chemother Pharmacol. 2008 Jan;61(1):105-11. Epub 2007
Apr 12.
2)
Continuous oral capecitabine at fixed dose in patients older than 75
years with metastatic colorectal and gastric cancer: a study of the
Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Petrioli R, Pascucci A, Francini E, Marsili S, Fiaschi AI, Civitelli
S, Tanzini G, Battistelli S, Lorenzi M, Roviello F, Francini G;
Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Anticancer Drugs. 2008 Jan;19(1):91-6.
3)
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in
the treatment of metastatic colorectal cancer.
Petrioli R, Paolelli L, Marsili S, Civitelli S, Francini E, Cioppa
T, Roviello F, Nettuno R, Intrivici C, Tanzini G, Lorenzi M,
Francini G.
Oncology.
2006;70(5):345-50. Epub 2006 Dec 15. |